The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 07, 2020
Filed:
Aug. 31, 2017
Applicant:
Rhizen Pharmaceuticals SA, La Chaux-de-Fonds, CH;
Inventors:
Prashant K. Bhavar, Hyderabad, IN;
Swaroop K. Vakkalanka, La Chaux-de-Fonds, CH;
Srikant Viswanadha, Hyderabad, IN;
Gayatri Swaroop Merikapudi, Hyderabad, IN;
Govindarajulu Babu, Hyderabad, IN;
Assignee:
RHIZEN PHARMACEUTICALS SA, La Chaux-de-Fonds, CH;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 417/14 (2006.01); C07D 417/06 (2006.01); C07D 285/135 (2006.01); A61K 31/433 (2006.01); A61K 31/44 (2006.01); A61K 31/4439 (2006.01); A61K 31/444 (2006.01); A61K 31/4965 (2006.01); A61K 31/497 (2006.01); A61K 31/501 (2006.01); A61K 31/505 (2006.01); A61K 31/506 (2006.01); A61K 45/06 (2006.01); C07D 213/75 (2006.01); C07D 239/42 (2006.01); C07D 241/20 (2006.01); C07D 401/12 (2006.01); C07D 417/08 (2006.01); A61K 31/4545 (2006.01); C07D 401/04 (2006.01);
U.S. Cl.
CPC ...
C07D 417/14 (2013.01); A61K 31/433 (2013.01); A61K 31/44 (2013.01); A61K 31/444 (2013.01); A61K 31/4439 (2013.01); A61K 31/4545 (2013.01); A61K 31/497 (2013.01); A61K 31/4965 (2013.01); A61K 31/501 (2013.01); A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61K 45/06 (2013.01); C07D 213/75 (2013.01); C07D 239/42 (2013.01); C07D 241/20 (2013.01); C07D 285/135 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 417/06 (2013.01); C07D 417/08 (2013.01); Y02A 50/422 (2018.01);
Abstract
The present disclosure provides compounds of formula (I) to (III) as glutaminase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders involving glutamine.